Hepatic enhancement and signal intensity analysis on magnetic resonance imaging as prognostic biomarkers in advanced chronic liver disease

Table 11 Incremental performance summary of hepatic enhancement models vs the reference model, n (%)

Endpoint	Horizon (months)	Added variable to reference model	Categorical NRI (95%CI)	NRI event1	NRI Non-event1	Continuous NRI % (95%CI)	ΔAUC2	ΔBrier2
Decompensation	12 months	+ HE segment VI	0.0 (-13.6; 12.9)	-	-	-13.6 (-58.7; 31.0)	-0.002	+0.001
		+ HE global	0.0 (-14.6; 14.3)	-	-	+0.34 (-44.3; 45.5)	-0.003	+0.0008
	24 months	+ HE segment VI	+2.9 (0.0; 7.6)	0.0	+2.9	+9.5 (-33.1; 51.2)	+0.002	-0.0006
		+ HE global	+7.1 (1.5; 13.9)	0.0	+7.1	+21.9 (-20.6; 62.4)	+0.0029	-0.00038
Mortality	12 months	+ HE segment VI	+30.7 (1.0; 68.8)	+28.6	+2.2	+13.7 (-68.0; 94.3)	+0.012	+0.0001
		+ HE global	+31.8 (2.0; 69.9)	+28.6	+3.2	+24.4 (-58.8; 107.4)	+0.011	-0.0011
	24 months	+ HE segment VI	+5.6 (-23.9; 35.6)	0.0	+5.6	+12.2 (-53.4; 76.6)	+0.012	+0.0005
		+ HE global	+6.7 (-24.4; 36.7)	0.0	+6.7	+41.1 (-26.3; 107.9)	+0.006	-0.0004

¹“-”: Component not required because total net reclassification improvement was 0. The reference model: Functional Liver Imaging Score + Model for End-Stage Liver Disease 3.0 + etiology + prior hepatocellular carcinoma status.

²Signs indicate change from the reference model; absolute values are provided in the text.

ΔAUC: Area under the curve of hepatic enhancement model - area under the curve of reference model; AUC: Area under the curve; CI: Confidence interval; ΔBrier: Brier score of hepatic enhancement model - Brier score of reference model; NRI: Net reclassification improvement; HE: Hepatic enhancement.